Who makes IV Bisphosphonate q 4 weeks?

IV Bisphosphonate q 4 weeks is developed by Amgen.

What development phase is IV Bisphosphonate q 4 weeks in?

IV Bisphosphonate q 4 weeks is in Phase 2.

Last reviewed 2026-04-19 · How we verify

IV Bisphosphonate q 4 weeks

Amgen · Phase 2 active Small molecule

At a glance

Generic name	IV Bisphosphonate q 4 weeks
Sponsor	Amgen
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer (PHASE3)
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IV Bisphosphonate q 4 weeks CI brief — competitive landscape report
IV Bisphosphonate q 4 weeks updates RSS · CI watch RSS
Amgen portfolio CI